PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of “Buy” by Analysts

PDS Biotechnology Co. (NASDAQ:PDSB) has been given an average rating of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $14.25.

Several research analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research report on Thursday, October 24th. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. Finally, StockNews.com raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Friday.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PDSB. Vanguard Group Inc. raised its stake in PDS Biotechnology by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares during the period. Blair William & Co. IL raised its stake in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the period. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology during the 2nd quarter valued at $55,000. Cubist Systematic Strategies LLC acquired a new stake in PDS Biotechnology during the 2nd quarter valued at $146,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in PDS Biotechnology during the 2nd quarter valued at $115,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $3.20 on Friday. The business’s fifty day moving average price is $3.24 and its two-hundred day moving average price is $3.27. The stock has a market cap of $117.82 million, a PE ratio of -2.62 and a beta of 1.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same period last year, the firm posted ($0.37) EPS. On average, analysts forecast that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.